Pharming Group N.V. (PINKSHEETS: PHGUF) Leiden, The Netherlands, August 4, 2008. Biotech company Pharming Group NV ("Pharming") (NYSE Euronext: PHARM) announced today that its inclusion in the Amsterdam Midkap Index (AMX-index) has been confirmed by NYSE Euronext.
The AMX-index is composed of the top 25 actively traded mid caps on NYSE Euronext Amsterdam, following the top 25 large cap companies. The companies in AMX are selected for the index based on turnover of shares in euros over the past 12 months (July 2007 - June 2008). The inclusion of Pharming will come into effect on September 2, 2008.
For further information on the Amsterdam Midkap Index and to obtain daily information on the indexes, please visit http://www.nyse.com.
About Pharming Group NV Pharming Group NV is developing innovative products for the treatment of genetic disorders, ageing diseases, specialty products for surgical indications, intermediates for various applications and nutritional products. Pharming has two products in late stage development - Rhucin® for Hereditary Angioedema and human lactoferrin for use in food products. The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, technology and processes for the purification and formulation of these products, as well as technology in the field of DNA repair (via DNage). Additional information is available on the Pharming website, http://www.pharming.com and on http://www.dnage.nl.
This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements.
Contact:
Carina Hamaker, Investor Voice, T: +31 (0)6 537 499 59 or T: +31 (0)71 52 47 400 Julia Philips (UK), Financial Dynamics, T: +44 (0)20 7269 7187 or T: +44 (0)7770 827 263 Samir Singh (US), Pharming Group NV, T: +1 908 720 6224 Rein Strijker, Pharming Group NV, T: +31 (0)71 52 47 400
LINK: http://hugin.info/132866/R/1240331/266052.pdf
Pharming Group N.V.
http://www.pharming.com
ISIN: NL0000377018
Stock Identifier: XAMS.PHARM
US: PINKSHEETS: PHGUF
The AMX-index is composed of the top 25 actively traded mid caps on NYSE Euronext Amsterdam, following the top 25 large cap companies. The companies in AMX are selected for the index based on turnover of shares in euros over the past 12 months (July 2007 - June 2008). The inclusion of Pharming will come into effect on September 2, 2008.
For further information on the Amsterdam Midkap Index and to obtain daily information on the indexes, please visit http://www.nyse.com.
About Pharming Group NV Pharming Group NV is developing innovative products for the treatment of genetic disorders, ageing diseases, specialty products for surgical indications, intermediates for various applications and nutritional products. Pharming has two products in late stage development - Rhucin® for Hereditary Angioedema and human lactoferrin for use in food products. The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, technology and processes for the purification and formulation of these products, as well as technology in the field of DNA repair (via DNage). Additional information is available on the Pharming website, http://www.pharming.com and on http://www.dnage.nl.
This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements.
Contact:
Carina Hamaker, Investor Voice, T: +31 (0)6 537 499 59 or T: +31 (0)71 52 47 400 Julia Philips (UK), Financial Dynamics, T: +44 (0)20 7269 7187 or T: +44 (0)7770 827 263 Samir Singh (US), Pharming Group NV, T: +1 908 720 6224 Rein Strijker, Pharming Group NV, T: +31 (0)71 52 47 400
LINK: http://hugin.info/132866/R/1240331/266052.pdf
Pharming Group N.V.
http://www.pharming.com
ISIN: NL0000377018
Stock Identifier: XAMS.PHARM
US: PINKSHEETS: PHGUF
| Tweet |
 |
Related Companies |
>>> Pharming Group N.V. |
| |
Related Industry Topics: |
European Finance News | |
| |
This Page Viewed: (Last 30 Days: 30) (Since Published: 2400) |
Events & Exhibitions
|
Site Search
| ENGLISH All Languages |
Upcoming WebCasts
 | Mr Mark Paton CEO Cue Energy Resources Tuesday, June 12, 2012 |
 | Mr Alan Hopkins CEO Pan Asia Corporation Tuesday, June 12, 2012 |
 | Mr Barry Dawes Martin Place Securities Tuesday, June 12, 2012 |
 | Dr Andrea Grant CEO Living Cell Technologies Monday, July 02, 2012 |
Companies in the News
Mobile Video TV
|
||
|
||
